260 related articles for article (PubMed ID: 27056898)
1. Telomerase reverse transcriptase promoter mutations in hepatitis B virus-associated hepatocellular carcinoma.
Yang X; Guo X; Chen Y; Chen G; Ma Y; Huang K; Zhang Y; Zhao Q; Winkler CA; An P; Lyu J
Oncotarget; 2016 May; 7(19):27838-47. PubMed ID: 27056898
[TBL] [Abstract][Full Text] [Related]
2. Clinical significance of combined circulating TERT promoter mutations and miR-122 expression for screening HBV-related hepatocellular carcinoma.
Trung NT; Hoan NX; Trung PQ; Binh MT; Van Tong H; Toan NL; Bang MH; Song LH
Sci Rep; 2020 May; 10(1):8181. PubMed ID: 32424223
[TBL] [Abstract][Full Text] [Related]
3. Hepatitis B Virus-Telomerase Reverse Transcriptase Promoter Integration Harnesses Host ELF4, Resulting in Telomerase Reverse Transcriptase Gene Transcription in Hepatocellular Carcinoma.
Sze KM; Ho DW; Chiu YT; Tsui YM; Chan LK; Lee JM; Chok KS; Chan AC; Tang CN; Tang VW; Lo IL; Yau DT; Cheung TT; Ng IO
Hepatology; 2021 Jan; 73(1):23-40. PubMed ID: 32170761
[TBL] [Abstract][Full Text] [Related]
4. Comprehensive analyses of mutations and hepatitis B virus integration in hepatocellular carcinoma with clinicopathological features.
Kawai-Kitahata F; Asahina Y; Tanaka S; Kakinuma S; Murakawa M; Nitta S; Watanabe T; Otani S; Taniguchi M; Goto F; Nagata H; Kaneko S; Tasaka-Fujita M; Nishimura-Sakurai Y; Azuma S; Itsui Y; Nakagawa M; Tanabe M; Takano S; Fukasawa M; Sakamoto M; Maekawa S; Enomoto N; Watanabe M
J Gastroenterol; 2016 May; 51(5):473-86. PubMed ID: 26553052
[TBL] [Abstract][Full Text] [Related]
5. Androgen Receptor Enhances Hepatic Telomerase Reverse Transcriptase Gene Transcription After Hepatitis B Virus Integration or Point Mutation in Promoter Region.
Li CL; Li CY; Lin YY; Ho MC; Chen DS; Chen PJ; Yeh SH
Hepatology; 2019 Feb; 69(2):498-512. PubMed ID: 30070724
[TBL] [Abstract][Full Text] [Related]
6. Tumor specific mutations in TERT promoter and CTNNB1 gene in hepatitis B and hepatitis C related hepatocellular carcinoma.
Pezzuto F; Izzo F; Buonaguro L; Annunziata C; Tatangelo F; Botti G; Buonaguro FM; Tornesello ML
Oncotarget; 2016 Aug; 7(34):54253-54262. PubMed ID: 27276713
[TBL] [Abstract][Full Text] [Related]
7. Suppression of PROX1-mediated TERT expression in hepatitis B viral hepatocellular carcinoma.
Kim YJ; Yoo JE; Jeon Y; Chong JU; Choi GH; Song DG; Jung SH; Oh BK; Park YN
Int J Cancer; 2018 Dec; 143(12):3155-3168. PubMed ID: 29987895
[TBL] [Abstract][Full Text] [Related]
8. Distinct Patterns of HBV Integration and
Jang JW; Kim HS; Kim JS; Lee SK; Han JW; Sung PS; Bae SH; Choi JY; Yoon SK; Han DJ; Kim TM; Roberts LR
Int J Mol Sci; 2021 Jun; 22(13):. PubMed ID: 34209079
[TBL] [Abstract][Full Text] [Related]
9. Common telomerase reverse transcriptase promoter mutations in hepatocellular carcinomas from different geographical locations.
Cevik D; Yildiz G; Ozturk M
World J Gastroenterol; 2015 Jan; 21(1):311-7. PubMed ID: 25574106
[TBL] [Abstract][Full Text] [Related]
10. Promoter hypermethylation of TERT is associated with hepatocellular carcinoma in the Han Chinese population.
Zhang H; Weng X; Ye J; He L; Zhou D; Liu Y
Clin Res Hepatol Gastroenterol; 2015 Oct; 39(5):600-9. PubMed ID: 25683523
[TBL] [Abstract][Full Text] [Related]
11. Diagnostic and Prognostic Roles of Serum Osteopontin and Osteopontin Promoter Polymorphisms in Hepatitis B-related Hepatocellular Carcinoma.
Chimparlee N; Chuaypen N; Khlaiphuengsin A; Pinjaroen N; Payungporn S; Poovorawan Y; Tangkijvanich P
Asian Pac J Cancer Prev; 2015; 16(16):7211-7. PubMed ID: 26514514
[TBL] [Abstract][Full Text] [Related]
12. Prediction of the prognosis of advanced hepatocellular carcinoma by TERT promoter mutations in circulating tumor DNA.
Hirai M; Kinugasa H; Nouso K; Yamamoto S; Terasawa H; Onishi Y; Oyama A; Adachi T; Wada N; Sakata M; Yasunaka T; Onishi H; Shiraha H; Takaki A; Okada H
J Gastroenterol Hepatol; 2021 Apr; 36(4):1118-1125. PubMed ID: 32830343
[TBL] [Abstract][Full Text] [Related]
13. TERT promoter mutation in resectable hepatocellular carcinomas: a strong association with hepatitis C infection and absence of hepatitis B infection.
Chen YL; Jeng YM; Chang CN; Lee HJ; Hsu HC; Lai PL; Yuan RH
Int J Surg; 2014; 12(7):659-65. PubMed ID: 24866078
[TBL] [Abstract][Full Text] [Related]
14. Frequent somatic TERT promoter mutations and CTNNB1 mutations in hepatocellular carcinoma.
Lee SE; Chang SH; Kim WY; Lim SD; Kim WS; Hwang TS; Han HS
Oncotarget; 2016 Oct; 7(43):69267-69275. PubMed ID: 27661004
[TBL] [Abstract][Full Text] [Related]
15. Human Telomerase Reverse Transcriptase Gene Promoter Mutation in Serum of Patients with Hepatocellular Carcinoma.
Ako S; Nouso K; Kinugasa H; Matsushita H; Terasawa H; Adachi T; Wada N; Takeuchi Y; Mandai M; Onishi H; Ikeda F; Shiraha H; Takaki A; Fujioka S; Mimura T; Okada H
Oncology; 2020; 98(5):311-317. PubMed ID: 32135540
[TBL] [Abstract][Full Text] [Related]
16. Telomerase reverse transcriptase promoter mutation is an early somatic genetic alteration in the transformation of premalignant nodules in hepatocellular carcinoma on cirrhosis.
Nault JC; Calderaro J; Di Tommaso L; Balabaud C; Zafrani ES; Bioulac-Sage P; Roncalli M; Zucman-Rossi J
Hepatology; 2014 Dec; 60(6):1983-92. PubMed ID: 25123086
[TBL] [Abstract][Full Text] [Related]
17. Combined use of murine double minute-2 promoter methylation and serum AFP improves diagnostic efficiency in hepatitis B virus-related hepatocellular carcinoma.
Wang JW; Qian Y; Wu CS; Zhao NH; Fang Y; Yuan XD; Gao S; Fan YC; Wang K
Int J Med Sci; 2020; 17(18):3190-3199. PubMed ID: 33173438
[No Abstract] [Full Text] [Related]
18. TERT Promoter Mutation in Serum Cell-Free DNA Is a Diagnostic Marker of Primary Hepatocellular Carcinoma in Patients with Nonalcoholic Fatty Liver Disease.
Akuta N; Kawamura Y; Kobayashi M; Arase Y; Saitoh S; Fujiyama S; Sezaki H; Hosaka T; Kobayashi M; Suzuki Y; Suzuki F; Ikeda K; Kumada H
Oncology; 2021; 99(2):114-123. PubMed ID: 32998139
[TBL] [Abstract][Full Text] [Related]
19. Detection of TERT promoter mutation in serum cell-free DNA using wild-type blocking PCR combined with Sanger sequencing in hepatocellular carcinoma.
Akuta N; Suzuki F; Kobayashi M; Fujiyama S; Kawamura Y; Sezaki H; Hosaka T; Kobayashi M; Saitoh S; Arase Y; Ikeda K; Suzuki Y; Kumada H
J Med Virol; 2020 Dec; 92(12):3604-3608. PubMed ID: 32100879
[TBL] [Abstract][Full Text] [Related]
20. Recurrent TERT promoter mutations identified in a large-scale study of multiple tumour types are associated with increased TERT expression and telomerase activation.
Huang DS; Wang Z; He XJ; Diplas BH; Yang R; Killela PJ; Meng Q; Ye ZY; Wang W; Jiang XT; Xu L; He XL; Zhao ZS; Xu WJ; Wang HJ; Ma YY; Xia YJ; Li L; Zhang RX; Jin T; Zhao ZK; Xu J; Yu S; Wu F; Liang J; Wang S; Jiao Y; Yan H; Tao HQ
Eur J Cancer; 2015 May; 51(8):969-76. PubMed ID: 25843513
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]